Researchers we empower:
Empowering Biotech & Pharma Research
Realize research and organizational values by using our highly accurate and stable human renal ciPTEC cell lines
Increase successful compounds to market
It is very important that research is focussed on the most promising compounds at an early stage. Working with compounds that show to be toxic in later stages of clinical research is an unfortunate waste of work and investment. Therefore, it is essential for researchers and organizations to increase the chance of success as early as possible. We have demonstrated this with multinational biotech and pharmaceutical companies like AstraZeneca. A validation set of 62 drugs, tested across a relevant concentration range compared to their exposure in humans, to develop a model that integrates multi-parametric data and drug exposure information, which identified most proximal tubular toxic drugs tested (sensitivity 75%) without any false positives (specificity 100%).
Reduce losses during clinical stages of drug development
Renal Toxicity accounts for 20% of all failures realized during the clinical stages of drug development. Losses incurred from these failures are significantly high and can be reduced by screening for renal toxicity during preclinical stages of drug development with ciPTEC. Together with the pharmaceutical industry, we have demonstrated that ciPTEC is highly specific and compatible with the needs in early stages of drug development. Using our established methods, ciPTEC allows you to mitigate the risk for renal toxicity caused by your lead compounds.
Evolve your insight on renal toxicity mechanisms
The functional drug transporters and endocytic apparatus lead to a realistic cellular response to toxicant exposures. This evolved insight on the detailed renal toxic mechanisms utilizes a higher chance to reach market successfully. Our experts in the field of pharmacology and toxicology can support you to elucidate the underlying mechanism of renal adverse effects observed in your lead compounds by developing cell-based assays based on our ciPTEC technology.
Create highly reproducible research
Cell4Pharma’s ciPTEC technology is based on a human renal cell line with unlimited proliferation capacity. Our cells have stable drug transport functionality for at least 20 passages. When creating your own stock, this means your assay will provide the same data, over and over again. Allowing for research to be valuable and reproducible organization wide.
Empowering Biotech & Pharma Research
Realize research and organizational values by using our highly accurate and stable human renal ciPTEC cell lines
Increase successful compounds to market
It is very important that research is focussed on the most promising compounds at an early stage. Working with compounds that show to be toxic in later stages of clinical research is an unfortunate waste of work and investment. Therefore, it is essential for researchers and organizations to increase the chance of success as early as possible. We have demonstrated this with multinational biotech and pharmaceutical companies like AstraZeneca. A validation set of 62 drugs, tested across a relevant concentration range compared to their exposure in humans, to develop a model that integrates multi-parametric data and drug exposure information, which identified most proximal tubular toxic drugs tested (sensitivity 75%) without any false positives (specificity 100%).
Create highly reproducible research
Cell4Pharma’s ciPTEC technology is based on a human renal cell line with unlimited proliferation capacity. Our cells have stable drug transport functionality for at least 20 passages. When creating your own stock, this means your assay will provide the same data, over and over again. Allowing for research to be valuable and reproducible organization wide.
Reduce losses during clinical stages of drug development
Renal Toxicity accounts for 20% of all failures realized during the clinical stages of drug development. Losses incurred from these failures are significantly high and can be reduced by screening for renal toxicity during preclinical stages of drug development with ciPTEC. Together with the pharmaceutical industry, we have demonstrated that ciPTEC is highly specific and compatible with the needs in early stages of drug development. Using our established methods, ciPTEC allows you to mitigate the risk for renal toxicity caused by your lead compounds.
Evolve your insight on renal toxicity mechanisms
The functional drug transporters and endocytic apparatus lead to a realistic cellular response to toxicant exposures. This evolved insight on the detailed renal toxic mechanisms utilizes a higher chance to reach market successfully. Our experts in the field of pharmacology and toxicology can support you to elucidate the underlying mechanism of renal adverse effects observed in your lead compounds by developing cell-based assays based on our ciPTEC technology.
ciPTEC Cell Lines Characteristics
Human origin
ciPTEC was originally derived from a human donor (female). The human origin results in the high predictivity for human renal adverse events and the versatile use of ciPTEC in the fields of pharmacology, nephrology, physiology and human pathology.
Robust data
The stable transfection and maintained epithelial characteristics lead to a cell line that will produce very robust data. Our validation studies demonstrated robust data for more than 20 passages.
Biomarker expression upon toxicant exposure
In screening assays developed by Cell4Pharma, (non-)specific biomarkers for renal toxicity could be demonstrated upon toxicant exposure, including HO-1, miRNAs and LDH release.
Intact drug transporter functionality
Using fluorescent probes specific for a transporter, we could demonstrate the functional expression of OCT2, P-glycoprotein, MRP4, BCRP and OAT1 (in ciPTEC-OAT1) and OAT3 (in ciPTEC-OAT3). The transport of fluorescent probes could be inhibited using specific inhibitors or competitors.
Suitable for drug-drug interaction studies
The transport of specific fluorescent probes could be inhibited using specific inhibitors or competitors, which can also be used to study drug-drug-interactions.
Relevant drug transporter expression
Following characterization on a protein and gene level, we demonstrated specific transporter expression (OCT2, P-glycoprotein, MRP4, BCRP) in ciPTEC. Following stable transfection using vectors containing the human OAT1 and OAT3, we created ciPTEC-OAT1 and ciPTEC-OAT3 models.
Compatible with high throughput screening
Cell4Pharma’s ciPTEC can be cultured in 96 and 384 well plates. Together with it’s unlimited proliferation capacity allow high throughput screening.
Unlimited proliferation from cryo stocks
Just as any cell line, ciPTEC can be stored in liquid nitrogen to create your own stock. Upon thawing, ciPTEC will proliferate at 33°C and maintain it’s characteristics.
Proximal tubular epithelial characteristics
Extensive characterization demonstrated that ciPTEC in culture keeps its proximal tubular epithelial characteristics, such as specific transporter expression (OCT2, P-glycoprotein, MRP4, BCRP, NaPi2), gamma-glutamyl transferase expression, ZO-1 and CD13 expression, as well as the formation of cilia.
Sector Values
Low inter-laboratory
variations
Compatible with high-throughput screening equipment
Easy to use following standard culturing protocols
Expression of specific biomarkers for renal toxicity upon toxicant exposure
Unlimited proliferation
capacity
Applicable in Organ-on-a-Chip devices to mimic 3D tubular structures
Testimonials
Because the cell line is robust in culture, the research leads to reliable results. As far as I am concerned, there is currently no kidney epithelial cell line available with an equally good predictive value for the human kidney.
The ciPTEC mimics primary renal cells, but you can culture them for a long time without losing their properties. The expression of transporters gives a more accurate response to drugs and toxins. The cells grow fast and are easy to handle.
ciPTEC is a well-accepted in vitro model to screen compounds for their DIKI potential.